UCSF HELEN DILLER FAMILY COMPREHENSIVE CANCER CENTER
kmUU300MXic
kmUU300MXic
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Presentations<br />
Phase II trials of cetuximab plus combined modality therapy (CMT) in<br />
squamous cell carcinoma of the anal canal (SCCAC) with and without<br />
human immunodeficiency virus (HIV) infection.<br />
Authors*: Madhur Garg, Fengmin Zhao, Jeannette Y. Lee, Joseph A. Sparano, Joel Palefsky, David H. Henry,<br />
William Wachsman, Lakshmi Rajdev, David Michael Aboulafia, Lee Ratner, Lisa A. Kachnic, Edith P. Mitchell,<br />
Adedayo A. Onitilo, Ronald T. Mitsuyasu, Al Bowen Benson<br />
Abstract #: 3522<br />
Presentation Date/Time: Saturday, June 4: 8:00 - 11:30 AM<br />
Location: Hall A Poster Board # 219<br />
Session: Gastrointestinal (Colorectal) Cancer<br />
Citation: J Clin Oncol 34, 2016 (suppl; abstr 3522)<br />
__________________________________________________________________________<br />
Blood-based biomarkers in patients (pts) with metastatic colorectal<br />
cancer (mCRC) treated with FOLFOX or FOLFIRI plus bevacizumab<br />
(Bev), cetuximab (Cetux), or bev plus Cetux: Results from CALGB<br />
80405 (Alliance).<br />
Authors*: Andrew B. Nixon, Alexander Sibley, Ace Joseph Hatch, Yingmiao Liu, Chen Jiang, Flora Mulkey,<br />
Mark D. Starr, John C. Brady, Donna Niedzwiecki, Federico Innocenti, Alan P. Venook, Howard S. Hochster,<br />
Heinz-Josef Lenz, Bert H. O’Neil, Kouros Owzar, Herbert Hurwitz<br />
Abstract #: 3597<br />
Presentation Date/Time: Saturday, June 4: 8:00 - 11:30 AM<br />
Location: Hall A, Poster Board #294<br />
Session: Gastrointestinal (Colorectal) Cancer<br />
Citation: J Clin Oncol 34, 2016 (suppl; abstr 3597)<br />
Venook Research Interests: Dr. Alan Venook is a nationally renowned expert in colorectal and liver cancers at<br />
the <strong>UCSF</strong> Helen Diller Family Comprehensive Cancer Center. He is highly regarded for his expertise in the<br />
effective use of the newest approaches and therapies to the treatment of colorectal cancer, as well treating<br />
primary and metastatic tumors to the liver. Dr. Venook has chaired and/or authored six major studies within<br />
the cooperative groups and he now Chairs the GI Committee of the Alliance for Clinical Trials in Oncology<br />
(formerly CALGB.)<br />
http://cancer.ucsf.edu/people/profiles/venook_alan.3698<br />
*<strong>UCSF</strong> authors in bold<br />
9
Change language